Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Over the past decade, growing medication complexity and costs have highlighted the importance of systematic drug optimization. Comprehensive medication management (CMM) focuses on individualized assessment of all patient medications for appropriateness, effectiveness, safety, and adherence. This approach could be valuable for patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD), where precise management reduces the risk of disease progression and complications. This study primarily aims to examine the impact of CMM on relevant clinical outcomes in T2D and CKD (systolic blood pressure (SBP), LDL, HbA1c). The secondary and tertiary aims include assessing CMM’s effectiveness in attenuating the progression of CKD among T2D patients and evaluating the alignment of CMM-guided therapy with established treatment guidelines for T2D and CKD.
A prospective, non-randomized pre–post interventional study was conducted at the Health Centre Zagreb - Centar from May 2023 to September 2025. Adults with T2D and at least one estimated glomerular filtration rate (eGFR) value below 60 mL/min/1.73 m², monitored for a minimum of six months, were included. The intervention group (IG) received standard care plus pharmacist-led CMM. Data collected included sociodemographic and clinical parameters, and medication use with follow-up assessments of T2D, hyperlipidemia (HLP), and arterial hypertension (AH) status. The control group (CG) received standard care managed by general practitioners, with parallel data collection.
The IG (n=47) showed significant improvements in HbA1c (−0.75 [0.3–1.75]; p<0.001), SBP (−11.3 ± 15.4 mmHg; p<0.0001), and LDL (−0.47 ± 0.86 mmol/L; p<0.001). In the CG (n=46), HbA1c (0.0 [−0.2–0.6]; p=0.189) and LDL (0.00 [−0.20–0.34]; p=0.586) remained unchanged, while SBP decreased significantly (−10.0 ± 22.0 mmHg; p=0.002). Target achievement in the IG improved for hypertension (25% to 42%), hyperlipidemia (19.6% to 47.7%), and T2D (30.4% to 72.7%), whereas in the CG, a significant improvement was observed only for T2D (39.1% to 54.3%; p=0.035). No statistically significant difference in median eGFR decline was detected between the two cohorts which may be attributable to the substantially shorter follow-up period (median 9 months compared with 22 months in controls, p<0.001). In the IG, SGLT2 inhibitor use increased from 36.2% to 63.8% (p<0.001) and metformin use from 38.3% to 55.3% (p=0.011). In the CG, SGLT2 inhibitors rose slightly from 23.9% to 30.4% (p=0.083), while metformin use declined from 66.7% to 64.4% (p=0.655).
Patients receiving CMM service demonstrated superior clinical outcomes inT2D and CKD. Optimized pharmacotherapy, including increased initiation of agents with established cardio-renal-metabolic benefits, contributed to better control of glycemia, lipids, and blood pressure. The absence of significant eGFR changes likely reflects the limited duration of follow-up. These findings support the broader adoption of CMM to improve comprehensive chronic disease management.
